OKYO Pharma Limited has filed for Fast Track designation with the U.S. FDA for its drug urcosimod, aimed at treating neuropathic corneal pain, a painful eye condition currently lacking an FDA-approved ...
Urcosimod is currently being evaluated in a phase 2 trial evaluating it's efficacy and safety in adults with neuropathic corneal pain. OKYO Pharma has filed a Fast Track designation application with ...
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results